Table S5 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
Key Points
Key points are not available for this paper at this time.
Abstract
Table S5. Preliminary mutation analysis
KI fragen
Like
Bookmark
Share
KI fragen
Like
Bookmark
Share
Table S5 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation | Synapse